LncRNA FTH1P3: A New Biomarker for Cancer-Related Therapeutic Development

Overview

Journal Curr Mol Med

Publisher Bentham Science Publishers

Specialty Molecular Biology

Date 2023 Jul 26

PMID 37491858

Authors

Maryam Darvish

Affiliations

Soon will be listed here.

Abstract

Cancer is a persistent and urgent health problem that affects the entire world. Not long ago, regulatory biomolecules referred to as long noncoding RNAs (lncRNAs) might have value for their innate abundance and stability. These single-stranded RNAs potentially interfere with several physiological and biochemical cellular processes involved in many human pathological situations, particularly cancer diseases. Ferritin heavy chain1 pseudogene 3 (FTH1P3), a lncRNA that is ubiquitously transcribed and belongs to the ferritin heavy chain (FHC) family, represents a novel class of lncRNAs primarily found in oral squamous cell carcinoma. Further research has shown that FTH1P3 is involved in other malignancies such as uveal melanoma, glioma, esophageal squamous cell carcinoma, non-small cell lung cancer, breast cancer, laryngeal squamous cell carcinoma, and cervical cancer. Accordingly, FTH1P3 significantly enhances cancer symptoms, including cell proliferation, invasion, metastasis, chemoresistance, and inhibition of apoptosis through many specific mechanisms. Notably, the clinical data significantly demonstrated the association of FTH1P3 overexpression with poor prognosis and poor overall survival within the examined samples. Here, we summarize all the research published to date (13 articles) on FTH1P3, focusing on the biological function underlying the regulatory mechanism and its possible clinical relevance.

References

Torre L, Siegel R, Ward E, Jemal A . Global Cancer Incidence and Mortality Rates and Trends--An Update. Cancer Epidemiol Biomarkers Prev. 2015; 25(1):16-27. DOI: 10.1158/1055-9965.EPI-15-0578. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Wang W, Kandimalla R, Huang H, Zhu L, Li Y, Gao F . Molecular subtyping of colorectal cancer: Recent progress, new challenges and emerging opportunities. Semin Cancer Biol. 2018; 55:37-52. PMC: 6240404. DOI: 10.1016/j.semcancer.2018.05.002. View

Zugazagoitia J, Guedes C, Ponce S, Ferrer I, Molina-Pinelo S, Paz-Ares L . Current Challenges in Cancer Treatment. Clin Ther. 2016; 38(7):1551-66. DOI: 10.1016/j.clinthera.2016.03.026. View

Hojman P, Gehl J, Christensen J, Pedersen B . Molecular Mechanisms Linking Exercise to Cancer Prevention and Treatment. Cell Metab. 2017; 27(1):10-21. DOI: 10.1016/j.cmet.2017.09.015. View

Porta C, Paglino C, Mosca A . Targeting PI3K/Akt/mTOR Signaling in Cancer. Front Oncol. 2014; 4:64. PMC: 3995050. DOI: 10.3389/fonc.2014.00064. View

Kalnina Z, Meistere I, Kikuste I, Tolmanis I, Zayakin P, Line A . Emerging blood-based biomarkers for detection of gastric cancer. World J Gastroenterol. 2015; 21(41):11636-53. PMC: 4631966. DOI: 10.3748/wjg.v21.i41.11636. View

Liu W, Yang Q, Liu B, Zhu Z . Serum proteomics for gastric cancer. Clin Chim Acta. 2014; 431:179-84. DOI: 10.1016/j.cca.2014.02.001. View

Lee M, Kim J, Jang M, Park C, Lee J, Lee T . Introduction of Nanomaterials to Biosensors for Exosome Detection: Case Study for Cancer Analysis. Biosensors (Basel). 2022; 12(8). PMC: 9405681. DOI: 10.3390/bios12080648. View

10.

Shahverdi M, Darvish M . Exosomal microRNAs: A Diagnostic and Therapeutic Small Bio-molecule in Esophageal Cancer. Curr Mol Med. 2022; 23(4):312-323. DOI: 10.2174/1566524022666220321125134. View

11.

Iyer M, Niknafs Y, Malik R, Singhal U, Sahu A, Hosono Y . The landscape of long noncoding RNAs in the human transcriptome. Nat Genet. 2015; 47(3):199-208. PMC: 4417758. DOI: 10.1038/ng.3192. View

12.

Xing C, Sun S, Yue Z, Bai F . Role of lncRNA LUCAT1 in cancer. Biomed Pharmacother. 2020; 134:111158. DOI: 10.1016/j.biopha.2020.111158. View

13.

Kung J, Colognori D, Lee J . Long noncoding RNAs: past, present, and future. Genetics. 2013; 193(3):651-69. PMC: 3583990. DOI: 10.1534/genetics.112.146704. View

14.

Nair L, Chung H, Basu U . Regulation of long non-coding RNAs and genome dynamics by the RNA surveillance machinery. Nat Rev Mol Cell Biol. 2020; 21(3):123-136. PMC: 7107043. DOI: 10.1038/s41580-019-0209-0. View

15.

Li M, Gou H, Tripathi B, Jiang S, Dubois W, Waybright T . An Apela RNA-Containing Negative Feedback Loop Regulates p53-Mediated Apoptosis in Embryonic Stem Cells. Cell Stem Cell. 2015; 16(6):669-83. PMC: 4458197. DOI: 10.1016/j.stem.2015.04.002. View

16.

Karami Fath M, Benam S, Salmani K, Naderi S, Fahham Z, Ghiabi S . Circular RNAs in neuroblastoma: Pathogenesis, potential biomarker, and therapeutic target. Pathol Res Pract. 2022; 238:154094. DOI: 10.1016/j.prp.2022.154094. View

17.

Klec C, Prinz F, Pichler M . Involvement of the long noncoding RNA NEAT1 in carcinogenesis. Mol Oncol. 2018; 13(1):46-60. PMC: 6322192. DOI: 10.1002/1878-0261.12404. View

18.

Smolle M, Pichler M . The Role of Long Non-Coding RNAs in Osteosarcoma. Noncoding RNA. 2018; 4(1). PMC: 5890394. DOI: 10.3390/ncrna4010007. View

19.

Chen Y, Li C, Pan Y, Han S, Feng B, Gao Y . The Emerging Role and Promise of Long Noncoding RNAs in Lung Cancer Treatment. Cell Physiol Biochem. 2016; 38(6):2194-206. DOI: 10.1159/000445575. View

20.

Chen X, Fan S, Song E . Noncoding RNAs: New Players in Cancers. Adv Exp Med Biol. 2016; 927:1-47. DOI: 10.1007/978-981-10-1498-7_1. View